Ivermectin inhibits cell proliferation and the expression levels of type I collagen, α‑SMA and CCN2 in hypertrophic scar fibroblasts

Tian,Song; Zheng,Yongjun; Xiao,Shichu; Luo,Pengfei; Sun,Rongju; Liu,Jun; Xia,Zhaofan

doi:10.3892/mmr.2021.12127

Ivermectin inhibits cell proliferation and the expression levels of type I collagen, α‑SMA and CCN2 in hypertrophic scar fibroblasts

Authors:
- Song Tian
- Yongjun Zheng
- Shichu Xiao
- Pengfei Luo
- Rongju Sun
- Jun Liu
- Zhaofan Xia
View Affiliations

Affiliations: Department of Burn Surgery, The First Affiliated Hospital of Naval Medical University, Shanghai 200433, P.R. China, Department of Pharmacology and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
Published online on: April 29, 2021 https://doi.org/10.3892/mmr.2021.12127
Article Number: 488

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A hypertrophic scar (HPS) is characterized by abnormal cell proliferation and the overproduction of extracellular matrix. Currently, the treatment options available for this remain unsatisfactory. Innovative treatments are required to attenuate or prevent hypertrophic scarring and the present study searched for a drug capable of becoming a new preventative and therapeutic strategy. Although the underlying mechanisms have not been fully clarified; it is widely accepted that the TGF‑β1/SMAD3 signaling pathway serves an essential role in HPS formation. In the present study, a compound library consisting of clinically used drugs was screened for their inhibitory activity against the SMAD3 protein. The results indicated that ivermectin was able to suppress the phosphorylation of SMAD3. Therefore, the present study further investigated whether ivermectin exhibited antifibrotic effects on HPS fibroblasts. The results demonstrated that ivermectin inhibited the proliferation of HPS ﬁbroblasts and significantly decreased the production of type I collagen, α‑smooth muscle actin and cellular communication network factor 2, as determined by analyzing the mRNA and protein expression levels. In conclusion, the results of the present study suggested that ivermectin may be a promising therapeutic agent for HPS.

View Figures

View References

1	Finnerty CC, Jeschke MG, Branski LK, Barret JP, Dziewulski P and Herndon DN: Hypertrophic scarring: The greatest unmet challenge after burn injury. Lancet. 388:1427–1436. 2016. View Article : Google Scholar : PubMed/NCBI
2	Zhang J, Li Y, Bai X, Li Y, Shi J and Hu D: Recent advances in hypertrophic scar. Histol Histopathol. 33:27–39. 2018.PubMed/NCBI
3	Lebonvallet N, Laverdet B, Misery L, Desmouliere A and Girard D: New insights into the roles of myofibroblasts and innervation during skin healing and innovative therapies to improve scar innervation. Exp Dermatol. 27:950–958. 2018. View Article : Google Scholar : PubMed/NCBI
4	Zhu Z, Ding J, Shankowsky HA and Tredget EE: The molecular mechanism of hypertrophic scar. J Cell Commun Signal. 7:239–252. 2013. View Article : Google Scholar : PubMed/NCBI
5	Yamanaka O, Saika S, Ikeda K, Miyazaki K, Kitano A and Ohnishi Y: Connective tissue growth factor modulates extracellular matrix production in human subconjunctival fibroblasts and their proliferation and migration in vitro. Jpn J Ophthalmol. 52:8–15. 2008. View Article : Google Scholar : PubMed/NCBI
6	Kiritsi D and Nystrom A: The role of TGF beta in wound healing pathologies. Mech Ageing Devt. 172:51–58. 2018. View Article : Google Scholar : PubMed/NCBI
7	Flanders KC: Smad3 as a mediator of the fibrotic response. Int J Exp Pathol. 85:47–64. 2004. View Article : Google Scholar : PubMed/NCBI
8	Terada Y, Hanada S, Nakao A, Kuwahara M, Sasaki S and Marumo F: Gene transfer of Smad7 using electroporation of adenovirus prevents renal fibrosis in post-obstructed kidney. Kidney Int. 61 (1 Suppl):S94–S98. 2002. View Article : Google Scholar : PubMed/NCBI
9	Wu C, Jiang J, Boye A, Jiang Y and Yang Y: Compound Astragalus and Salvia miltiorrhiza extract suppresses rabbits' hypertrophic scar by modulating the TGF-β/Smad signal. Dermatology. 229:363–368. 2014. View Article : Google Scholar : PubMed/NCBI
10	Mun JH, Kim YM, Kim BS, Kim JH, Kim MB and Ko HC: Simvastatin inhibits transforming growth factor-β1-induced expression of type I collagen, CTGF, and α-SMA in keloid fibroblasts. Wound Repair Regen. 22:125–133. 2014. View Article : Google Scholar : PubMed/NCBI
11	Zhang GY, Yi CG, Li X, Ma B, Li ZJ, Chen XL, Guo SZ and Gao WY: Troglitazone suppresses transforming growth factor-beta1-induced collagen type I expression in keloid fibroblasts. Br J Dermatol. 160:762–770. 2009. View Article : Google Scholar : PubMed/NCBI
12	Lynagh T, Webb TI, Dixon CL, Cromer BA and Lynch JW: Molecular determinants of ivermectin sensitivity at the glycine receptor chloride channel. J Biol Chem. 286:43913–43924. 2011. View Article : Google Scholar : PubMed/NCBI
13	Dominguez-Gomez G, Chavez-Blanco A, Medina-Franco JL, Saldivar-Gonzalez F, Flores-Torrontegui Y, Juarez M, Diaz-Chavez J, Gonzalez-Fierro A and Duenas-Gonzalez A: Ivermectin as an inhibitor of cancer stem-like cells. Mol Med Rep. 17:3397–3403. 2018.PubMed/NCBI
14	Deeks ED: Ivermectin: A review in rosacea. Am J Clin Dermatol. 16:447–452. 2015. View Article : Google Scholar : PubMed/NCBI
15	Tang B, Zhu B, Liang Y, Bi L, Hu Z, Chen B, Zhang K and Zhu J: Asiaticoside suppresses collagen expression and TGF-β/Smad signaling through inducing Smad7 and inhibiting TGF-βRI and TGF-βRII in keloid fibroblasts. Arch Dermatol Res. 303:563–572. 2011. View Article : Google Scholar : PubMed/NCBI
16	Qin T, Lu XT, Li YG, Liu Y, Yan W, Li N and Sun YY: Effect of Period 2 on the proliferation, apoptosis and migration of osteosarcoma cells, and the corresponding mechanisms. Oncol Lett. 16:2668–2674. 2018.PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Sidgwick GP and Bayat A: Extracellular matrix molecules implicated in hypertrophic and keloid scarring. J Eur Acad Dermatol Venereol. 26:141–152. 2012. View Article : Google Scholar : PubMed/NCBI
19	Verrecchia F and Mauviel A: Transforming growth factor-beta and fibrosis. World J Gastroenterol. 13:3056–3062. 2007. View Article : Google Scholar : PubMed/NCBI
20	Kajdaniuk D, Marek B, Borgiel-Marek H and Kos-Kudla B: Transforming growth factor β1 (TGFβ1) in physiology and pathology. Endokrynol Pol. 64:384–396. 2013. View Article : Google Scholar : PubMed/NCBI
21	Yu R and Cen Y: Transforming growth factor beta1/Smad3 signal transduction pathway and post-traumatic scar formation. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 26:330–335. 2012.(In Chinese). PubMed/NCBI
22	Leask A and Abraham DJ: TGF-beta signaling and the fibrotic response. FASEB J. 18:816–827. 2004. View Article : Google Scholar : PubMed/NCBI
23	Liang CJ, Yen YH, Hung LY, Wang SH, Pu CM, Chien HF, Tsai JS, Lee CW, Yen FL and Chen YL: Thalidomide inhibits fibronectin production in TGF-β1-treated normal and keloid fibroblasts via inhibition of the p38/Smad3 pathway. Biochem Pharmacol. 85:1594–602. 2013. View Article : Google Scholar : PubMed/NCBI
24	Biernacka A, Dobaczewski M and Frangogiannis NG: TGF-beta signaling in fibrosis. Growth Factors. 29:196–202. 2011. View Article : Google Scholar : PubMed/NCBI
25	Chin GS, Liu W, Peled Z, Lee TY, Steinbrech DS, Hsu M and Longaker MT: Differential expression of transforming growth factor-beta receptors I and II and activation of Smad 3 in keloid fibroblasts. Plast Reconstr Surg. 108:423–429. 2001. View Article : Google Scholar : PubMed/NCBI
26	Wang Z, Gao Z, Shi Y, Sun Y, Lin Z, Jiang H, Hou T, Wang Q, Yuan X, Zhu X, et al: Inhibition of Smad3 expression decreases collagen synthesis in keloid disease fibroblasts. J Plast Reconstr Aesthet Surg. 60:1193–1199. 2007. View Article : Google Scholar : PubMed/NCBI
27	Gauglitz GG, Korting HC, Pavicic T, Ruzicka T and Jeschke MG: Hypertrophic Scarring and Keloids: Pathomechanisms and current and emerging treatment strategies. Mol Med. 17:113–125. 2011. View Article : Google Scholar : PubMed/NCBI
28	Linge C, Richardson J, Vigor C, Clayton E, Hardas B and Rolfe K: Hypertrophic scar cells fail to undergo a form of apoptosis specific to contractile collagen-the role of tissue transglutaminase. J Invest Dermatol. 125:72–82. 2005. View Article : Google Scholar : PubMed/NCBI
29	Luo S, Benathan M, Raffoul W, Panizzon RG and Egloff DV: Abnormal balance between proliferation and apoptotic cell death in fibroblasts derived from keloid lesions. Plast Reconstr Surg. 107:87–96. 2001. View Article : Google Scholar : PubMed/NCBI
30	Wolfram D, Tzankov A, Pulzl P and Piza-Katzer H: Hypertrophic scars and keloids-a review of their pathophysiology, risk factors, and therapeutic management. Dermatol Surg. 35:171–181. 2009. View Article : Google Scholar : PubMed/NCBI
31	Gu L, Zhu YJ, Yang X, Guo ZJ, Xu WB and Tian XL: Effect of TGF-beta/Smad signaling pathway on lung myofibroblast differentiation. Acta Pharmacol Sin. 28:382–391. 2007. View Article : Google Scholar : PubMed/NCBI
32	Conte E, Gili E, Fagone E, Fruciano M, Iemmolo M and Vancheri C: Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci. 58:13–19. 2014. View Article : Google Scholar : PubMed/NCBI
33	Darby IA, Laverdet B, Bonté F and Desmoulière A: Fibroblasts and myofibroblasts in wound healing. Clin Cosmet Investig Dermatol. 7:301–311. 2014.PubMed/NCBI
34	Meran S and Steadman R: Fibroblasts and myofibroblasts in renal fibrosis. Int J Exp Patho. 92:158–167. 2011. View Article : Google Scholar : PubMed/NCBI
35	Colwell AS, Phan TT, Kong W, Longaker MT and Lorenz PH: Hypertrophic scar fibroblasts have increased connective tissue growth factor expression after transforming growth factor-beta stimulation. Plast Reconstr Surg. 116:1387–1992. 2005. View Article : Google Scholar : PubMed/NCBI